BIO Comments on FDA Draft Guidance on Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease
February 15, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease.
BIO welcomes the FDA’s efforts to provide clear, concise guidance on the regulatory and scientific framework for product developers of targeted treatments. This will help sponsors with clinical trial development, including the types/levels of evidence to support a grouping strategy for clinical trial eligibility and benefit-risk evaluation approaches within a disease exhibiting differences in molecular subset.
BIO encourages the FDA to continue to gather stakeholder input on the development of targeted therapies to ensure the guidance keeps pace with scientific advances. BIO’s comments include additional suggestions to clarify the guidance, the scope, and FDA’s receptivity to innovative approaches for the development of targeted therapies.
Download Full Comments Below
BIO Letter Low-Frequency Molecular Subsets FINAL 2-15-18
One thing that we can all agree on is the need to give our children a fighting chance so they can lead long and productive lives. That is why it is critical to pass the bipartisan Give Kids a Chance Act and ensure the Pediatric Priority Review…
Dear Colleagues, This month marks my one-year anniversary as BIO's CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request for Comments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease.
BIO welcomes the FDA’s efforts to provide clear, concise guidance on the regulatory and scientific framework for product developers of targeted treatments. This will help sponsors with clinical trial development, including the types/levels of evidence to support a grouping strategy for clinical trial eligibility and benefit-risk evaluation approaches within a disease exhibiting differences in molecular subset.
BIO encourages the FDA to continue to gather stakeholder input on the development of targeted therapies to ensure the guidance keeps pace with scientific advances. BIO’s comments include additional suggestions to clarify the guidance, the scope, and FDA’s receptivity to innovative approaches for the development of targeted therapies.